The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease

Lockhat, Farhana B.; Emembolu, J.O.; Konje, Justin C.

doi:10.1093/humrep/deh004

Cited by 124 publications

(61 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Contraceptive Methodssupporting

confidence: 76%

“…This finding was confirmed by other prospective observational studies with similar sample sizes, in some cases with failed previous medical and surgical attempts to treat pain (179,180). Reported compliance beyond 6 and 12 months in different series were 68% and 82%, respectively (179,180). Eighty percent of removals took place within the first year after insertion and were determined mainly by persistent pain, although irregular bleeding and weight gain were also reported (179,180).…”

Section: Contraceptive Methodssupporting

confidence: 76%

“…Reported compliance beyond 6 and 12 months in different series were 68% and 82%, respectively (179,180). Eighty percent of removals took place within the first year after insertion and were determined mainly by persistent pain, although irregular bleeding and weight gain were also reported (179,180). Longer follow-up periods of up to 3 years revealed a statistically significant reduction in dysmenorrhea scores, with up to 87.5% of patients who maintained the device reporting improvement in pain according to a visual analogue scale (VAS) (180,181).…”

Section: Contraceptive Methodsmentioning

confidence: 95%

See 2 more Smart Citations

Pharmacologic therapies in endometriosis: a systematic review

Soares¹,

Martínez-Varea

Hidalgo-Mora

et al. 2012

Fertility and Sterility

138

View full text Add to dashboard Cite

Section: Contraceptive Methodssupporting

confidence: 76%

Section: Contraceptive Methodssupporting

confidence: 76%

Section: Contraceptive Methodsmentioning

confidence: 95%

See 1 more Smart Citation

Pharmacologic therapies in endometriosis: a systematic review

Soares¹,

Martínez-Varea

Hidalgo-Mora

et al. 2012

Fertility and Sterility

138

View full text Add to dashboard Cite

“…17 Other studies have demonstrated improved symptoms associated with rectovaginal endometriosis and a significant decrease in the extent of disease observed at second-look laparoscopy after 6 months of treatment with the LNG-IUS. 18,19 Relief of endometriosis pain with the LNG-IUS is similar to GnRH-a. 20 …”

Section: Progestogensmentioning

confidence: 99%

Medical treatment of endometriosis: an update

Ezzat¹

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Endometriosis is defined as the presence of endometrial-like tissue (glands and stroma) outside the uterus, which induces a chronic inflammatory reaction, scar tissue, and adhesions that may distort a woman’s pelvic anatomy. Endometriosis is primarily found in young women, but its occurrence is not related to ethnic or social group distinctions. Patients with endometriosis mainly complain of pelvic pain, dysmenorrhea, and dyspareunia. Endometriosis is a very common debilitating disease that occurs in 6 to 10% of the general female population; in women with pain, infertility, or both, the frequency is 35-50%. This is an evidence based narrative review conducted by searching Medline up to (2017) and other online articles from Pubmed, Google scholar by using terms like Endometriosis, management, evidence based, updated treatment, pharmacoceutical hormon treatment and non-hormonal treatment. Articles were selected based on their currency and relevance to the discussion. Numerous cofactors can play a role in the progression and maintenance of endometriosis, which is thus a complex multifactorial disease. Hormonal therapy represents the treatment of choice in patients with endometriosis; with this in mind, we could consider CAM a supplementary option to be added to hormonal treatment, or as a valuable opportunity for those women in whom medical therapy is contraindicated.

show abstract

“…The use of the LNG-IUS fulfils the longtime treatment concept, which is necessary in women with endometriosis/adenomyosis, if there is no desire to become pregnant. The LNG-IUS is an effective method not only to alleviate dysmenorrhea and lower abdominal pain [17,18] but also the endometriosis lesions and adenomyosis lesions regress [19,20].…”

Section: Progestogen Treatment Of Peritoneal Endometriosismentioning

confidence: 99%

Hormonal contraceptives and endometriosis/adenomyosis

Schindler¹

2010

Gynecological Endocrinology

View full text Add to dashboard Cite

Over the past 50 years hormonal contraceptives have gradually developed to be cost-effective medical treatment modalities for primary and secondary therapy of endometriosis/adenomyosis. This is particularly true for the various estrogen/ progestogen combinations as monophasic -particularly progestogen-dominant -preparations in cyclic, long-cyclic and continuous treatment forms. An alternative is the progestogen-only therapy used continuously. Therapeutic effects have been shown for peritoneal, ovarian and deep-infiltrating endometriosis as well as for adenomyosis. An individualized, medical long-term treatment concept to control endometriosis/adenomyosis-related symptoms, endometriosis/adenomyosis development and minimizing the recurrence rate needs to be further studied in women, who do not desire to become pregnant.

show abstract

The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease

Cited by 124 publications

References 23 publications

Pharmacologic therapies in endometriosis: a systematic review

Pharmacologic therapies in endometriosis: a systematic review

Medical treatment of endometriosis: an update

Hormonal contraceptives and endometriosis/adenomyosis

Contact Info

Product

Resources

About